Medical Licensing (MD/DO) · Independent exam preparation
Family Medicine Certification Examination Study Guide
Practise diagnostic distinctions, safe chronic therapy, urgent stabilization, and preventive decisions across ABFM's five domains with cases and explained drills.
By CertMedbry · Updated 17 October 2026
Practise deciding when antibiotics help, how routine diabetes and hypertension care should be individualized, which symptoms demand immediate action, and how preventive decisions change with risk. This selective guide develops 60 clinical and evidence-based decisions across ABFM's five clinical-activity domains. The official ABFM outline defines the full examination scope, including adult, pediatric, maternity, gynecologic, mental-health, surgical, community, and older-patient care beyond these examples. Use the cases to explain your reasoning, then test it with 20 original questions and 20 recall cards.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
The official name is the Family Medicine Certification Examination, also called the one-day exam. This guide uses initial ABFM certification as its organizing pathway. The 2026 booklet states that initial and continuing certification candidates take the same examination. The workbook wording 'American Board of Family Medicine (ABFM) Certification Examination' refers to this examination.
ABFM — One-Day Exam: Become Certified · 2026 Family Medicine Certification Examination Information Booklet
How many questions are there, and how many are scored?
There are 300 presented questions, arranged in four sections of 75. A numerical scored-versus-pretest breakdown is not specified in the cited 2026 examination materials reviewed. The total presented count therefore should not be represented as a verified scored-question count.
ABFM — One-Day Exam: Continue Certification · 2026 Family Medicine Certification Examination Information Booklet
How much time is available?
Each of the four sections lasts 95 minutes, providing 380 minutes of question time. An additional 100 minutes of pooled break time may be divided between the three section breaks. These figures describe section and break allowances, rather than every component of the testing appointment.
How is the examination delivered, and can answers be reviewed?
Prometric administers the examination at test centers in a secure, standardized computer-based format. Within the active section, candidates may move backward and forward, mark questions, and change answers before time expires. Once a section is completed or its time expires, its questions cannot be reopened.
ABFM — One-Day Exam: Become Certified · ABFM — One-Day Exam: Continue Certification
Which question styles should candidates expect?
ABFM specifies single-best-answer multiple-choice questions, including clinical scenarios. Its general testing tutorial may demonstrate other formats, but ABFM explicitly states that the one-day exam uses only single-best-answer multiple-choice questions. The questions in this guide are independent learning drills and do not predict an examination result.
ABFM — One-Day Exam: Continue Certification · 2026 Family Medicine Certification Examination Information Booklet
Which blueprint applies to the 2026 examination?
The clinical-activity blueprint implemented January 1, 2025 applies. Its targets are Acute Care and Diagnosis 35%, Chronic Care Management 25%, Emergent and Urgent Care 20%, Preventive Care 15%, and Foundations of Care 5%. The 2026 issuer-linked booklet is labeled v.1.0. The official outline and booklet establish the full scope; these 60 concepts are selective. Domains classify the clinical activity: ambulatory diagnostic investigation belongs in Acute Care and Diagnosis even when the suspected disease is chronic.
ABFM — Family Medicine Exam Blueprint · ABFM — New in 2025: Redesigned Family Medicine Exam Blueprint · 2026 Family Medicine Certification Examination Information Booklet
How do longitudinal assessment and alternative eligibility pathways relate to this guide?
ABFM's longitudinal assessment shares the clinical-activity blueprint but is a separate assessment option with its own participation requirements. Its format is not represented by this one-day-exam guide. Resident entry, AOA training, certification entry or re-entry, and specified reciprocity routes have different eligibility requirements; those requirements do not create different versions of the one-day examination.
ABFM — New in 2025: Redesigned Family Medicine Exam Blueprint · 2026 Family Medicine Certification Examination Information Booklet
Which jurisdiction and guideline dates govern the clinical examples?
The examination is administered by the American Board of Family Medicine. Screening examples explicitly use the cited US Preventive Services Task Force recommendations: colorectal and lung cancer recommendations from 2021 and osteoporosis screening from January 14, 2025. Other references retain their own dates, including KDIGO 2024, the 2022 heart-failure guideline, NHLBI's 2020 asthma focused updates, and the 2025 AHA/ACC hypertension framework. UK professional-college references support specified clinical principles without implying UK certification eligibility or importing UK service arrangements.
2026 Family Medicine Certification Examination Information Booklet · USPSTF — Colorectal Cancer: Screening · USPSTF — Lung Cancer: Screening · USPSTF — Osteoporosis to Prevent Fractures: Screening
Independent educational material for physicians preparing for ABFM's one-day Family Medicine Certification Examination, with initial certification as the organizing pathway. This is specialty board certification. The material is independently authored and is not endorsed by ABFM.
Outline used: 2026 Family Medicine Certification Examination Information Booklet, issuer-linked file labeled v.1.0; clinical-activity blueprint effective January 1, 2025, verified on October 9, 2026. The workbook label 'American Board of Family Medicine (ABFM) Certification Examination' maps to ABFM's official Family Medicine Certification Examination (one-day exam); the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Acute Care and Diagnosis35%
1.When does adult sinusitis suggest bacterial infection, and which initial antibiotics fit?
The illness trajectory is more useful than discharge color alone. CDC describes adult bacterial patterns as persistent symptoms for more than 10 days without improvement; severe symptoms lasting more than 3–4 days, with fever at least 39°C plus purulent nasal discharge or facial pain; or deterioration after initial improvement. Uncomplicated presentations generally do not require sinus radiographs. Observation remains reasonable when follow-up is reliable. When antibiotics are selected, amoxicillin or amoxicillin-clavulanate is first-line; routine azithromycin is discouraged because of pneumococcal resistance. Doxycycline or a respiratory fluoroquinolone can be alternatives for penicillin-allergic adults.
Apply it
An adult has nasal obstruction and facial pressure for 12 days without improvement. Identify the persistent bacterial pattern, assess complications, and discuss observation versus an appropriate antibiotic after reviewing allergy history.
Common pitfall: Green mucus during an improving cold does not establish bacterial sinusitis, and convenience does not overcome predictable antimicrobial resistance.
3.How should acute cough be screened for pneumonia?
For an otherwise healthy adult, pneumonia becomes less likely when vital signs are normal and the lung examination lacks focal abnormalities. CDC highlights heart rate at least 100/min, respiratory rate at least 24/min, temperature at least 38°C, and findings such as focal consolidation, egophony, or fremitus. These findings guide further evaluation rather than the color of sputum. The reassuring combination is population-specific and should not be stretched to dismiss illness in a vulnerable or clinically deteriorating patient.
Apply it
A healthy adult with cough has a temperature of 38.5°C, respiratory rate of 28/min, and focal right-sided crackles. Evaluate for pneumonia rather than assigning uncomplicated bronchitis based only on the short symptom duration.
Common pitfall: The absence of colored sputum does not exclude pneumonia, and a cough label should never replace assessment of vital signs and focal findings.
4.Why are antibiotics usually inappropriate for acute bronchitis?
Uncomplicated acute bronchitis is generally managed without antibiotics after pneumonia and other important diagnoses have been considered. Colored sputum reflects airway inflammation and does not establish bacterial infection. CDC advises against routine antibiotics regardless of cough duration. The useful clinical decision is whether the patient still fits the uncomplicated syndrome, not whether coughing has become frustrating. Symptom treatment should also be individualized because evidence for particular cough remedies is limited and adverse effects can outweigh modest relief.
Apply it
A healthy adult has nine days of cough with green sputum, normal vital signs, and clear lungs. Explain the expected inflammatory illness, offer appropriate symptom care, and give instructions to return for worsening symptoms.
Common pitfall: Persistent cough alone does not convert uncomplicated bronchitis into a bacterial infection; deterioration or new findings should trigger reassessment rather than automatic antibiotic prescribing.
5.How should pharyngitis testing and confirmed streptococcal treatment be linked?
Clear viral features, including cough, rhinorrhea, hoarseness, oral ulcers, or conjunctivitis, usually make group A streptococcal testing unnecessary. Without these features, examination alone cannot reliably separate streptococcal from viral pharyngitis. A positive rapid antigen test or throat culture supports treatment in the appropriate clinical setting. Penicillin or amoxicillin is preferred. Clarify any allergy reaction because immediate hypersensitivity changes suitable alternatives; macrolide and clindamycin resistance varies geographically.
Apply it
A child with cough, rhinorrhea, and conjunctivitis generally needs supportive care without strep testing. A child with a compatible nonviral presentation and positive throat culture should receive an appropriate antibiotic.
Common pitfall: Testing every red throat can identify streptococcal carriage during viral illness. Tonsillar redness alone neither establishes infection nor justifies antibiotics.
CDC — Clinical Guidance for Group A Streptococcal Pharyngitis · CDC — Outpatient Clinical Care for Pediatric Populations
6.How does age change follow-up of a negative rapid strep antigen test?
For symptomatic children aged three years or older with suspected group A streptococcal pharyngitis, a negative rapid antigen test should be followed by throat culture. Rapid antigen sensitivity varies, so arrange communication and treatment if culture is positive. Routine backup culture is generally unnecessary in adults because acute rheumatic fever is very rare in this group. Adults with a negative rapid antigen result generally should not receive antibiotics. Persistent, severe, or atypical illness still warrants diagnostic reassessment.
Apply it
Obtain a backup culture for an appropriately tested eight-year-old with a negative antigen result. In a stable adult with the same negative result, provide symptom care without routine backup culture.
Common pitfall: Do not apply adult follow-up rules to children or treat a clinical score as laboratory confirmation of streptococcal infection.
CDC — Clinical Guidance for Group A Streptococcal Pharyngitis · CDC — Outpatient Clinical Care for Adults
8.Which findings distinguish common causes of vaginal discharge?
History alone is insufficient to diagnose vaginitis. Combine examination with vaginal pH and appropriate microscopy or laboratory testing. A pH above 4.5 commonly accompanies bacterial vaginosis or trichomoniasis. Clue cells support bacterial vaginosis, motile trichomonads support trichomoniasis, and hyphae or budding yeast support candidiasis. Negative microscopy does not reliably exclude yeast or trichomoniasis; use additional testing when suspicion persists. See [CDC evaluation of vulvovaginal symptoms](https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm).
Apply it
A nonpregnant patient repeatedly self-treats discharge as yeast. Elevated pH and clue cells redirect evaluation toward bacterial vaginosis rather than another empirical antifungal course.
Common pitfall: Neither discharge appearance nor vaginal pH alone establishes the cause. Cervicitis and noninfectious irritation can also produce symptoms.
9.What findings establish acute otitis media?
Acute otitis media requires evidence of middle-ear effusion with compatible acute inflammation. Moderate or severe tympanic-membrane bulging, or new otorrhea not caused by otitis externa, supports diagnosis. Mild bulging requires recent ear pain or intense erythema. Pneumatic otoscopy or tympanometry helps establish effusion. A red membrane alone is insufficient because crying, fever, or irritation may alter appearance. Diagnostic precision prevents antibiotics from being used for ear discomfort without true acute middle-ear infection.
Apply it
A crying toddler has a red but mobile tympanic membrane without bulging or effusion. Reconsider acute otitis media and examine for other causes of discomfort rather than treating membrane redness as a definitive bacterial diagnosis.
Common pitfall: Ear pulling and erythema can be persuasive but nonspecific; do not diagnose acute otitis media when middle-ear effusion has not been demonstrated.
10.When is observation reasonable for acute otitis media?
Observation is an option for nonsevere unilateral AOM at ages 6–23 months and nonsevere unilateral or bilateral AOM at age 24 months or older, provided there is no otorrhea. Nonsevere means mild otalgia lasting less than 48 hours and temperature below 39°C. Use shared decision-making, analgesia, and dependable follow-up within 48–72 hours. Worsening or failure to improve requires reassessment and antibiotic initiation when indicated. Otorrhea, severe symptoms, or bilateral disease at ages 6–23 months warrants antibiotics rather than observation.
Apply it
A three-year-old has confirmed unilateral AOM, mild pain for 18 hours, temperature of 38°C, and no otorrhea. With dependable follow-up, offer analgesia and observation with reassessment within 48–72 hours.
Common pitfall: Moderate or severe otalgia, otalgia lasting at least 48 hours, temperature at least 39°C, or otorrhea excludes the nonsevere observation pathway.
AOM Symptom Severity and Treatment Options | eqipp.aap.org · CDC — Outpatient Clinical Care for Pediatric Populations
11.When should amoxicillin-clavulanate replace amoxicillin for otitis media?
Amoxicillin is generally first-line when antibiotics are indicated and the child has not recently received it. Amoxicillin-clavulanate is preferred when amoxicillin was used in the preceding 30 days, purulent conjunctivitis accompanies otitis, or recurrent disease has failed to respond to amoxicillin. These cues increase concern that plain amoxicillin may be inadequate. Clavulanate expands coverage against beta-lactamase-producing organisms; it should be selected for a reason rather than automatically used for every uncomplicated episode.
Apply it
A two-year-old requiring antibiotic treatment has a bulging tympanic membrane and purulent conjunctivitis. With no beta-lactam allergy, choose amoxicillin-clavulanate because the associated conjunctivitis changes the preferred initial coverage in this presentation.
Common pitfall: Broadening treatment solely because a membrane looks very red misses the relevant selection cues and exposes children to avoidable adverse effects without demonstrated benefit.
12.How does pediatric sinusitis severity change initial management?
Pediatric bacterial sinusitis can present as nasal discharge or daytime cough persisting more than 10 days without improvement, deterioration after initial improvement, or a severe presentation with fever at least 39°C and purulent nasal discharge for at least three consecutive days. CDC recommends antibiotics for severe or worsening disease. For uncomplicated persistent disease, observation may last up to three days, with reassessment and antibiotic treatment if symptoms deteriorate or fail to improve. The distinction is between an otherwise stable child whose symptoms are prolonged and a child whose severity or trajectory warrants immediate treatment. Routine imaging is unnecessary for uncomplicated cases and does not replace assessment of complications.
Apply it
A child improves after a cold, then develops new fever and worsening daytime cough. Recognize the worsening pattern and select antibiotic treatment rather than applying the observation option intended for uncomplicated persistent symptoms.
Common pitfall: The observation option is limited to up to three days for uncomplicated persistent pediatric sinusitis. Fever at least 39°C with purulent nasal discharge for at least three consecutive days, or deterioration after initial improvement, warrants antibiotics rather than this observation pathway.
13.What supports a clinical diagnosis of infant bronchiolitis?
Bronchiolitis typically affects children younger than two years and combines a viral upper-respiratory prodrome with cough, wheezing, tachypnea, or increased respiratory effort. In a typical presentation, routine laboratory testing and chest radiography are unnecessary. Management is supportive, including nasal suctioning and assessment of feeding, hydration, and respiratory status. CDC does not recommend routine outpatient albuterol, antibiotics, or corticosteroids. Atypical progression or severe distress changes the evaluation rather than validating routine testing for every infant.
Apply it
A seven-month-old develops rhinorrhea followed by cough and diffuse wheezing, while maintaining feeding and oxygenation. Use supportive care and monitoring instructions rather than automatically prescribing albuterol or antibiotics for the wheezing alone.
Common pitfall: Wheezing does not make every infant an asthma patient; applying an older child's bronchodilator treatment reflex can lead to ineffective treatment of typical bronchiolitis.
14.What should follow a concern about a young child's development?
A missed milestone or caregiver concern warrants developmental assessment rather than waiting for the next scheduled screening age. Milestone checklists support surveillance but do not replace standardized, validated screening tools. When delay is suspected, arrange further evaluation and early-intervention assessment in parallel; a final medical diagnosis is not required before requesting services. In the United States, children younger than three generally enter the early-intervention system, while children three or older can be evaluated through the public school system. See [CDC developmental concern guidance](https://www.cdc.gov/act-early/families/concerned.html) and [developmental monitoring and screening](https://www.cdc.gov/act-early/about/developmental-monitoring-and-screening.html).
Apply it
A caregiver reports concerns about a two-year-old's communication. Document specific abilities, use an appropriate validated screen, and arrange developmental and early-intervention evaluation instead of waiting until the 30-month visit.
Common pitfall: A reassuring brief office interaction does not invalidate concerns observed repeatedly at home, and a checklist is not a diagnostic assessment.
15.Which patients fit uncomplicated cystitis treatment guidance?
The CDC uncomplicated cystitis recommendations specifically address healthy, nonpregnant, premenopausal adult women. Dysuria, urgency, and frequent small voids support a lower urinary infection; nitrites and leukocyte esterase strengthen the diagnosis. Nitrofurantoin, fosfomycin, or trimethoprim-sulfamethoxazole when local resistance is below 20% are first-line options. Fever, flank pain, pregnancy, or significant complicating conditions move the case outside this simple framework. Fluoroquinolones should be reserved when other appropriate agents cannot be used.
Apply it
A healthy, nonpregnant 26-year-old has dysuria and urgency without fever or flank pain. A compatible urinalysis supports cystitis. Choose a recommended first-line agent after checking allergies, renal considerations, and relevant local susceptibility information.
Common pitfall: Do not apply a lower-tract treatment shortcut to a patient with flank pain or systemic illness; the uncomplicated cystitis population and syndrome are deliberately limited.
16.How do positional findings identify BPPV and guide treatment?
Brief, reproducible spinning triggered by changes in head position suggests BPPV. Dix-Hallpike-provoked vertigo with torsional, upbeating nystagmus supports posterior-canal disease. Treat with an appropriately sided canalith-repositioning procedure, such as the Epley maneuver, which moves displaced particles out of the affected canal. If Dix-Hallpike produces horizontal or no nystagmus despite a compatible history, perform or arrange a supine roll test for lateral-canal disease. Persistent symptoms require reassessment for unresolved BPPV or another disorder.
Apply it
Right-sided Dix-Hallpike testing produces brief vertigo and torsional, upbeating nystagmus. Offer a right posterior-canal repositioning maneuver rather than relying only on vestibular-suppressant medication.
Common pitfall: Dizziness alone during testing does not establish the canal pattern. Continuous vertigo or focal neurologic findings requires broader evaluation.
CPG-BPPV08-05-2017.pdf · AAO-HNS — BPPV: Dix-Hallpike and Canalith Repositioning
18.What does pregnancy of unknown location actually mean?
Pregnancy of unknown location describes a positive pregnancy test without a pregnancy located on ultrasound. It is a temporary classification, not a final diagnosis of ectopic pregnancy. Possibilities include an early intrauterine pregnancy, a pregnancy that has ended, and an ectopic pregnancy. In a stable patient, serial pregnancy-hormone measurements, repeat ultrasound, and clinical reassessment clarify the outcome. A single nondiagnostic scan or hormone value should not be used to assign location with unwarranted certainty.
Apply it
A stable patient has light spotting, a positive pregnancy test, and no pregnancy visible on transvaginal ultrasound. Arrange serial assessment and explicit warning signs rather than labeling the pregnancy ectopic or a completed miscarriage immediately.
Common pitfall: An empty uterus on one early scan does not distinguish an early viable pregnancy from pregnancy loss or ectopic pregnancy; uncertainty requires structured follow-up.
19.When should pelvic inflammatory disease be treated empirically?
In a sexually active patient at STI risk with otherwise unexplained pelvic or lower abdominal pain, cervical-motion, uterine, or adnexal tenderness supports presumptive PID treatment; all three are not required. Evaluate alternative causes, including pregnancy-related and surgical conditions. For eligible mild-to-moderate outpatient disease, CDC recommends ceftriaxone 500 mg intramuscularly once plus doxycycline 100 mg twice daily and metronidazole 500 mg twice daily for 14 days. For patients weighing more than 150 kg with documented gonococcal infection, CDC specifies ceftriaxone 1 g intramuscularly once instead of 500 mg. Lack of improvement within 72 hours requires reevaluation and escalation. See [CDC PID guidance](https://www.cdc.gov/std/treatment-guidelines/pid.htm).
Apply it
A nonpregnant 60-kg patient with STI risk, pelvic pain, cervical-motion tenderness, and no surgical emergency can receive the recommended outpatient regimen with reliable reassessment.
Common pitfall: Negative cervical gonorrhea or chlamydia testing does not exclude upper-tract infection. Pregnancy, abscess, severe illness, inability to tolerate oral treatment, or an unresolved surgical emergency favors hospitalization.
20.Which rash pattern most strongly suggests herpes zoster?
Herpes zoster typically produces grouped vesicles in one or two adjacent dermatomes, usually on one side without crossing the midline. Local pain, itching, or tingling may precede the eruption. The combination of neuropathic symptoms and a dermatomal vesicular distribution is more discriminating than vesicles alone. Immunocompromised patients can have atypical or generalized presentations, and facial involvement can threaten vision or hearing. Absence of a typical rash makes a purely clinical diagnosis less secure.
Apply it
An older adult develops burning right-sided chest pain followed by clustered vesicles in a narrow band that stops at the midline. Recognize the dermatomal pattern and assess whether any eye, ear, or disseminated involvement changes urgency.
Common pitfall: Do not assume all unilateral pain is zoster before a rash appears, or that an immunocompromised patient's widespread eruption excludes zoster because it is atypical.
21.When does pain after shingles meet the definition of postherpetic neuralgia?
CDC defines postherpetic neuralgia as pain in the area of the previous zoster rash that continues more than 90 days after rash onset. The reference point is rash onset, not the day the last lesion heals. Risk rises with age and with more severe pain or a larger eruption. Recognizing this complication separates persistent neural pain from ongoing visible skin infection and gives a clearer basis for explaining why pain can outlast the healed eruption.
Apply it
Four months after a thoracic zoster eruption began, a patient still has burning pain in the same area despite healed skin. Identify postherpetic neuralgia rather than assuming that continuing pain proves a new active eruption.
Common pitfall: Pain during the first few weeks of shingles is not automatically postherpetic neuralgia; apply the duration criterion and confirm that the distribution matches the previous rash.
22.How is chronic kidney disease distinguished from a single abnormal result?
Chronic kidney disease requires an abnormality of kidney structure or function present for at least three months with implications for health. Classification combines cause, GFR category, and albuminuria category because filtration and urine albumin provide complementary prognostic information. One low estimated GFR during acute illness does not establish chronicity. Conversely, preserved filtration does not exclude CKD when persistent markers of kidney damage are present. Reviewing prior measurements is therefore a diagnostic step, not just administrative record gathering.
Apply it
A dehydrated patient has an estimated GFR of 52 mL/min/1.73 m² with no previous results. Treat the acute problem, review historical data, and repeat assessment rather than immediately assigning a chronic stage from one value.
Common pitfall: Normal creatinine can coexist with albuminuric kidney disease, while an isolated low estimated GFR may reflect an acute process; neither measurement should stand alone.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
33.Which spirometric result confirms airflow obstruction in suspected COPD?
Under the GOLD framework, a post-bronchodilator FEV1/FVC below 0.70 demonstrates airflow obstruction; COPD diagnosis also requires a compatible clinical context. FEV1 is the volume exhaled in the first second; FVC is the total forced exhaled volume. For example, post-bronchodilator FEV1 of 1.8 L and FVC of 3.0 L give a ratio of 0.60, demonstrating obstruction on that examination. When the post-bronchodilator ratio is 0.60–0.80, GOLD recommends repeat spirometry on a separate occasion to confirm persistence because biological variability can change classification. FEV1 percent predicted helps grade airflow limitation after diagnosis and is not the diagnostic ratio. Imaging does not replace spirometry. See [GOLD Science Committee recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC11799884/).
Apply it
A former smoker with chronic cough and exertional dyspnea has post-bronchodilator FEV1/FVC of 0.62 and FEV1 of 68% predicted. The ratio demonstrates obstruction on this examination, but repeat spirometry on a separate occasion should confirm persistence because it lies within 0.60–0.80. The 68% predicted value describes a different measurement.
Common pitfall: Do not confuse FEV1/FVC below 0.70 with FEV1 below 70% predicted. A single ratio of 0.62 does not remove the need to confirm persistence, and smoking history with hyperinflation does not replace spirometry.
Spirometry Quick Guide - Global Initiative for Chronic Obstructive Lung Disease - GOLD · NHLBI — COPD: Diagnosis
34.When should alpha-1 antitrypsin deficiency be considered in COPD?
Alpha-1 antitrypsin deficiency is an inherited contributor to COPD and can also involve the liver. NHLBI advises discussing genetic screening after a COPD diagnosis, with particular attention to a family history of deficiency, COPD diagnosed in relatives in their forties or fifties, or liver disease. These clues broaden the causal assessment beyond tobacco exposure. Identifying an inherited contribution also has implications for relatives, making the family history clinically actionable rather than merely descriptive.
Apply it
A 44-year-old with confirmed COPD has little smoking exposure and a sibling with unexplained liver disease. Discuss alpha-1 antitrypsin evaluation and the potential relevance of a positive result to other family members.
Common pitfall: Do not dismiss an inherited cause because the patient has smoked; tobacco exposure and genetic susceptibility can coexist and contribute to the same clinical disease.
Chronic Care Management25%
2.How should uncomplicated primary hypertension treatment be selected?
The 2025 AHA/ACC framework recommends lifestyle measures plus medication for average systolic blood pressure at least 140 mm Hg or diastolic pressure at least 90 mm Hg. Start medication at average systolic pressure at least 130 mm Hg or diastolic pressure at least 80 mm Hg when cardiovascular disease, previous stroke, diabetes, CKD, or PREVENT 10-year cardiovascular risk of at least 7.5% is present. For lower-risk adults, begin lifestyle treatment and initiate medication if pressure remains at least 130/80 mm Hg after 3–6 months. Stage 2 hypertension generally warrants two first-line agents from different classes, preferably in one pill. First-line classes include thiazide-type diuretics, long-acting dihydropyridine calcium-channel blockers, ACE inhibitors, and ARBs. Choose agents around comorbidities, adverse effects, and adherence, with an overarching goal below 130/80 mm Hg subject to individual considerations. See [2025 AHA/ACC hypertension recommendations](https://professional.heart.org/en/science-news/2025-high-blood-pressure-guideline/top-things-to-know) and [first-line medication classes](https://newsroom.heart.org/news/combination-pills-for-high-blood-pressure-may-simplify-treatment-improve-long-term-health).
Apply it
A nonpregnant adult has confirmed average blood pressure of 154/94 mm Hg without acute organ injury. Combine lifestyle treatment with two appropriate first-line classes, such as an ARB and a long-acting dihydropyridine calcium-channel blocker, and monitor response.
Common pitfall: Do not combine an ACE inhibitor with an ARB. A smartwatch estimate should not substitute for reliable cuff-based measurements.
Combination pills for high blood pressure may simplify treatment, improve long-term health | American Heart Association · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
7.How should routine diabetes goals and monitoring be individualized?
A1C reflects average glycemia over approximately three months. A goal below 7% is appropriate for many adults, but severe hypoglycemia, limited life expectancy, and advanced complications can justify less stringent goals. Measure A1C at least twice yearly and more often when goals are unmet. Interpret it alongside glucose records because an average can conceal clinically important lows and highs. Routine management also addresses blood pressure, lipids, smoking, nutrition, and activity. See [NIDDK A1C guidance](https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test/) and [diabetes management](https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes).
Apply it
An older insulin-treated patient has A1C of 6.6% but recurrent symptomatic lows. Reassess the target and treatment intensity rather than calling the result optimal solely because A1C is below 7%.
Common pitfall: A satisfactory A1C does not exclude dangerous hypoglycemia or replace cardiovascular risk management.
17.How does CKD change routine type 2 diabetes medication selection?
KDIGO supports metformin for type 2 diabetes with CKD when estimated GFR is at least 30 mL/min/1.73 m², with renal monitoring and dose adjustment as function declines. An SGLT2 inhibitor is recommended for type 2 diabetes with CKD when estimated GFR is at least 20, providing kidney and cardiovascular protection beyond glucose lowering. If individualized glycemic goals remain unmet despite metformin and an SGLT2 inhibitor, or these cannot be used, a long-acting GLP-1 receptor agonist is recommended. Selection therefore incorporates kidney function and organ protection as well as A1C.
Apply it
A patient with type 2 diabetes, albuminuric CKD, and estimated GFR of 42 takes metformin. Assess addition of an SGLT2 inhibitor for kidney protection rather than considering only whether another drug is needed to lower A1C.
Common pitfall: Reassess metformin as renal function declines. Withhold SGLT2 inhibitors during prolonged fasting or critical illness. Before surgery or procedures involving prolonged fasting, withhold empagliflozin for at least three days and ertugliflozin for at least four days, when possible. Document the last dose and a postoperative restart plan. Reassess oral intake, hydration, clinical stability, and any concern for ketosis; restart only when the patient is stable, eating and drinking normally, and ketoacidosis is absent. If ketoacidosis occurred, confirm its resolution before restarting.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf · 204629s063lbl.pdf · 209803s008lbledt.pdf
23.Why does albuminuria influence selection of kidney-protective therapy?
Albuminuria signals kidney damage and helps identify patients who benefit from renin-angiotensin system inhibition. KDIGO recommends an ACE inhibitor or ARB for CKD with severely increased albuminuria without diabetes, and for moderately to severely increased albuminuria with diabetes. These drugs reduce intraglomerular pressure as well as systemic blood pressure. The treatment decision therefore uses both estimated GFR and urine albumin rather than assuming that every antihypertensive provides equivalent kidney protection.
Apply it
A patient with diabetes, hypertension, persistent albuminuria, and stable kidney function needs treatment adjustment. Consider an ACE inhibitor or ARB, document baseline potassium and creatinine, and plan monitoring rather than selecting therapy from blood pressure alone.
Common pitfall: A controlled office blood pressure does not erase the prognostic importance of albuminuria; renal protection and blood-pressure lowering overlap but are not identical treatment considerations.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
24.When should ACE inhibitor or ARB laboratory monitoring occur?
KDIGO advises checking blood pressure, serum creatinine, and potassium within two to four weeks after starting or increasing an ACE inhibitor or ARB, with timing influenced by baseline kidney function and potassium. These agents alter glomerular hemodynamics and can reduce potassium excretion. Monitoring detects clinically important adverse effects while allowing beneficial therapy to continue when tolerated. A prescription change is therefore incomplete without a follow-up plan and attention to volume status and interacting medicines.
Apply it
An ACE inhibitor dose is increased for albuminuric CKD. Arrange a blood-pressure review and repeat creatinine and potassium within two to four weeks, using earlier assessment when the patient's baseline risk warrants closer surveillance.
Common pitfall: Waiting for the next annual laboratory panel misses the period when a treatment-related creatinine or potassium change is most likely to affect immediate management.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
25.How should a creatinine rise after renin-angiotensin blockade be interpreted?
A modest creatinine increase can reflect the expected fall in intraglomerular pressure rather than structural kidney injury. KDIGO advises continuing ACE inhibitor or ARB therapy unless creatinine rises by more than 30% within four weeks after initiation or dose increase. A larger change prompts evaluation for contributing causes and treatment reassessment. Potassium, blood pressure, symptoms, volume status, and concurrent medicines still matter; the percentage threshold does not override symptomatic hypotension or uncontrolled hyperkalemia.
Apply it
Creatinine increases from 1.0 to 1.2 mg/dL after starting an ACE inhibitor. With stable blood pressure, normal potassium, and no volume depletion, recognize the 20% rise as compatible with continued treatment and monitoring.
Common pitfall: Stopping a protective drug for any creatinine increase sacrifices benefit; continuing it despite symptomatic hypotension or uncontrolled hyperkalemia misuses the percentage threshold as absolute reassurance.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
26.Why should ACE inhibitors and ARBs not be combined in CKD?
Dual renin-angiotensin blockade may appear attractive when albuminuria persists, but greater biochemical suppression does not establish a better clinical outcome. KDIGO recommends avoiding combinations of ACE inhibitors, ARBs, and direct renin inhibitors in CKD because adverse effects include hyperkalemia and kidney injury. The better strategy is to optimize one tolerated agent and consider other evidence-based approaches. A lower urine-protein measurement is not sufficient justification for a combination with an unfavorable benefit-harm balance.
Apply it
A patient taking a maximally tolerated ARB still has albuminuria. Do not add an ACE inhibitor merely to lower the albumin measurement; reassess adherence, risk factors, and other appropriate kidney-protective treatment options instead.
Common pitfall: A favorable surrogate response can conceal clinical harm. Do not interpret additional albuminuria reduction as proof that dual blockade is safer or more effective.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
27.Which medication classes form foundational HFrEF treatment?
Foundational HFrEF therapy comprises an ARNI, an evidence-based beta blocker, an MRA, and an SGLT2 inhibitor when appropriate. Sacubitril-valsartan combines neprilysin inhibition with angiotensin-receptor blockade; the guideline recommends ARNI therapy for eligible patients with NYHA class II–III symptoms to reduce morbidity and mortality. An ACE inhibitor is an alternative when ARNI is not feasible; an ARB is an alternative when ACE inhibitors are not tolerated and ARNI is not feasible. Separate an ACE inhibitor and ARNI by at least 36 hours. ARNI must not be given to patients with any history of angioedema.
Apply it
A stable patient with NYHA class II HFrEF takes a loop diuretic and an ACE inhibitor. Assess eligibility to replace the ACE inhibitor with sacubitril-valsartan, allowing at least a 36-hour washout and checking angioedema history, blood pressure, renal function, and potassium. Also assess the missing foundational classes.
Common pitfall: Never overlap an ACE inhibitor and sacubitril-valsartan. Relief of congestion does not establish complete outcome-directed therapy, and prior angioedema precludes ARNI treatment.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
28.Why can SGLT2 inhibitors benefit HFrEF without diabetes?
SGLT2 inhibitors are recommended for symptomatic chronic HFrEF to reduce heart-failure hospitalization and cardiovascular mortality irrespective of type 2 diabetes. Their role in this setting is therefore not limited to glucose lowering. A normal glycated hemoglobin is not a reason to overlook the class. Selection still requires assessment of contraindications, tolerability, renal considerations, and counseling about adverse effects. The indication comes from the heart-failure syndrome and demonstrated outcomes, rather than the presence of hyperglycemia.
Apply it
A patient with an ejection fraction of 30% remains symptomatic on other appropriate treatment and has no diabetes. Consider an SGLT2 inhibitor for its heart-failure benefit after reviewing clinical suitability and discussing treatment risks.
Common pitfall: Calling the class a diabetes medicine can obscure a separate heart-failure indication; a normal glucose level does not eliminate the demonstrated benefit in eligible HFrEF.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
29.Which beta blockers have established outcome benefits in HFrEF?
The evidence-based beta blockers identified in the heart-failure guideline are bisoprolol, carvedilol, and sustained-release metoprolol succinate. Their outcome evidence should not be generalized to every beta blocker or every formulation. In an appropriate stable patient, the goal is a tolerated regimen supported by heart-failure trials, rather than heart-rate reduction alone. Medication review should therefore verify the exact drug and formulation, particularly when a patient already takes a beta blocker for another indication.
Apply it
A stable patient with HFrEF takes metoprolol tartrate prescribed years earlier for palpitations. Review whether to use an evidence-based HFrEF regimen, recognizing that sustained-release metoprolol succinate is the formulation supported by the guideline.
Common pitfall: A shared drug stem does not prove equivalent trial evidence. Do not substitute immediate-release metoprolol tartrate for the specifically supported sustained-release formulation without recognizing the distinction.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
30.When can a mineralocorticoid receptor antagonist be added safely in HFrEF?
For symptomatic HFrEF with NYHA class II–IV symptoms, spironolactone or eplerenone reduces morbidity and mortality when renal function and potassium permit use. The guideline specifies estimated GFR greater than 30 mL/min/1.73 m² and serum potassium below 5.0 mEq/L for initiation. Potassium and renal function require close monitoring afterward. These eligibility checks matter because blocking aldosterone can retain potassium, making a beneficial class hazardous when baseline clearance or potassium balance is already unfavorable.
Apply it
A symptomatic HFrEF patient has an estimated GFR of 48 mL/min/1.73 m² and potassium of 4.3 mEq/L. Consider an MRA with planned monitoring rather than assuming that eligibility at initiation removes the need for follow-up.
Common pitfall: Do not add an MRA reflexively when potassium is already elevated or renal function falls outside initiation criteria; outcome benefit does not erase predictable safety limits.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
31.What should be checked before stepping up asthma treatment?
Before escalating treatment for poor asthma control, assess adherence, inhaler technique, environmental exposures, and comorbid conditions. A prescribed medicine cannot provide its expected effect if little reaches the lungs or doses are frequently missed. Reviewing these factors distinguishes inadequate treatment intensity from inadequate delivery or ongoing triggers. Control assessment also considers both current impairment and future exacerbation risk. A higher prescription step may be appropriate, but it should follow correction of identifiable barriers rather than substitute for that assessment.
Apply it
An adolescent reports frequent symptoms despite a controller prescription. Demonstration reveals poor inhaler coordination, and refill history suggests missed doses. Correct technique and adherence barriers before interpreting the prescription as a failed therapeutic trial.
Common pitfall: Escalating a dose without checking actual use can increase cost and adverse effects while leaving the main cause of poor control completely unchanged.
NHLBI — 2020 Focused Updates to the Asthma Management Guidelines
32.How does ICS-formoterol maintenance-and-reliever treatment work?
NHLBI recommends single-inhaler ICS-formoterol maintenance-and-reliever therapy, or SMART, for appropriate patients aged four years or older with moderate to severe persistent asthma. Formoterol provides rapid bronchodilation and each reliever inhalation also delivers corticosteroid. For the studied regimens delivering 4.5 micrograms of formoterol per inhalation, the maximum combined maintenance-plus-reliever total is eight inhalations daily at ages 4–11 and twelve daily at ages 12 or older. Patients needing more must contact their clinician. These counts cannot be transferred indiscriminately to other devices or strengths.
Apply it
An adult prescribed a suitable 4.5-microgram-per-inhalation formoterol combination takes four maintenance inhalations daily. Explain that maintenance and reliever inhalations together must not exceed twelve daily, leaving at most eight reliever inhalations within that ceiling. Needing more requires clinician contact; severe or rapidly worsening symptoms require urgent assessment.
Common pitfall: The daily ceiling includes scheduled doses. Do not treat twelve inhalations as an additional reliever allowance or substitute an ICS-salmeterol product for the formoterol regimen.
NHLBI — 2020 Focused Updates to the Asthma Management Guidelines
35.Which monitoring is essential during lithium treatment?
Lithium treatment requires monitoring of serum lithium concentration together with kidney and thyroid function. The concentration helps assess exposure, while organ-function testing identifies effects that a symptom review alone may miss. Monitoring is relevant during long-term maintenance as well as treatment changes. A patient who feels psychiatrically stable can still develop a clinically important laboratory abnormality. Medication review should therefore connect ongoing benefit with a reliable monitoring plan rather than regard stability as permission to stop safety surveillance.
Apply it
A patient receiving long-term lithium feels well but has not had laboratory monitoring recently. Arrange lithium concentration, renal assessment, and thyroid testing rather than renewing indefinitely on the basis of stable mood alone.
Common pitfall: A lithium level does not replace kidney or thyroid testing, and an apparently effective maintenance regimen does not make organ-function monitoring unnecessary over time.
36.Why should depressive presentations be assessed for previous mania?
A current depressive episode does not by itself establish unipolar depression. Prior periods of elevated or markedly irritable mood, increased activity, decreased need for sleep, grandiosity, or risky behavior may indicate bipolar illness. NIMH warns that antidepressant treatment without a mood stabilizer can trigger mania or rapid cycling when bipolar disorder is missed. The longitudinal history, sometimes clarified by family observations, therefore changes medication selection even when the patient currently appears only depressed.
Apply it
A patient requesting an antidepressant describes a previous week of little sleep without fatigue, excessive spending, and unusually increased activity. Investigate bipolar illness and avoid treating the history as routine unipolar depression without further assessment.
Common pitfall: Insomnia with exhaustion differs from a decreased need for sleep with sustained energy; overlooking that distinction can hide a previous manic or hypomanic episode.
Emergent and Urgent Care20%
37.How can anaphylaxis be recognized without hives?
Anaphylaxis is a rapidly evolving clinical emergency that can involve airway compromise, bronchospasm, hypotension, or shock after an exposure. Skin findings are common but are not required in every case. A sudden combination of respiratory and circulatory deterioration should therefore prompt treatment even when urticaria is absent. Waiting for a rash can permit progression to respiratory failure or cardiovascular collapse. Recognition depends on the exposure, timing, and organ-system findings rather than a single mandatory skin sign.
Apply it
Minutes after vaccination, a patient develops wheezing, throat tightness, and hypotension without a rash. Recognize anaphylaxis, give intramuscular epinephrine immediately, and activate emergency assistance while supporting airway, breathing, and circulation.
Common pitfall: Absence of hives does not exclude anaphylaxis. A patient with respiratory compromise and hypotension should not be observed untreated while waiting for skin findings.
38.How should adult anaphylaxis be treated and reassessed?
Give epinephrine 1 mg/mL at an adult dose of 0.3–0.5 mg intramuscularly in the mid-outer thigh, equivalent to 0.3–0.5 mL. Repeat every 5–15 minutes as needed. Epinephrine counteracts vasodilation, tissue swelling, and bronchospasm. Activate emergency assistance and provide positioning, airway support, oxygen, and isotonic fluid as indicated. Reassess breathing, perfusion, and mental status; fading hives alone do not establish recovery. Transfer for further evaluation and observation because symptoms can recur after initial improvement.
Apply it
An adult receives 0.5 mg intramuscular epinephrine for anaphylaxis. Wheezing improves but hypotension persists. Continue resuscitation, give fluids and repeat epinephrine as indicated, and arrange monitored transfer.
Common pitfall: Check concentration and dose. Antihistamines and corticosteroids do not replace epinephrine, and an intravenous bolus is not the initial intramuscular treatment.
39.How does the patient's ability to swallow change hypoglycemia treatment?
An alert person able to swallow safely can treat low glucose with 15–20 g of fast-acting glucose or carbohydrate, then recheck after 15 minutes and repeat if still low. Severe hypoglycemia requiring another person's assistance needs immediate rescue treatment. If consciousness or swallowing is impaired, avoid oral intake; administer available glucagon and activate emergency assistance. After recovery, review insulin or insulin-secretagogue exposure, missed meals, activity, and kidney function to prevent recurrence. See [NIDDK hypoglycemia guidance](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia).
Apply it
A conscious insulin-treated patient with glucose of 58 mg/dL can swallow and receives oral glucose with a 15-minute recheck. An unconscious patient instead requires emergency rescue treatment.
Common pitfall: Do not give food or drink to a patient who cannot protect the airway. Correction of one reading does not resolve the cause of recurrent episodes.
40.What diagnostic criteria allow recognition of euglycemic DKA?
The 2024 consensus requires all three components for DKA: glucose at least 200 mg/dL or established diabetes; beta-hydroxybutyrate at least 3.0 mmol/L or urine ketones at least 2+; and metabolic acidosis with pH below 7.3 and/or bicarbonate below 18 mmol/L. Established diabetes satisfies the first component even when glucose is below 200 mg/dL. SGLT2 inhibitors, reduced intake, and pregnancy can accompany euglycemic DKA. Glucose alone therefore cannot exclude DKA; ketones and acid-base status are essential.
Apply it
A patient with established type 2 diabetes taking an SGLT2 inhibitor has glucose of 178 mg/dL, beta-hydroxybutyrate of 4.2 mmol/L, pH of 7.25, and bicarbonate of 15 mmol/L. Recognize that all three DKA components are met despite glucose below 200 mg/dL.
Common pitfall: Modest glucose is not reassuring when established diabetes, qualifying ketonemia, and metabolic acidosis are present. Conversely, ketones alone without the other required components do not establish DKA.
Hyperglycaemic Crises in Adults with Diabetes: A Consensus Report
41.Why is blood beta-hydroxybutyrate preferred in suspected DKA?
Beta-hydroxybutyrate is the principal ketoacid produced in DKA. Direct blood measurement assesses it, whereas nitroprusside urine testing mainly detects acetoacetate. Urine testing can underestimate ketosis early and appear persistently abnormal during recovery as beta-hydroxybutyrate converts to acetoacetate. This biochemical mismatch can distort both diagnosis and assessment of response. Blood beta-hydroxybutyrate, interpreted with acid-base findings and the clinical picture, more directly evaluates the process responsible for the patient's ketoacidosis.
Apply it
A patient with suspected DKA has substantial acidosis but only weak urine ketones. Measure blood beta-hydroxybutyrate rather than using the urine result to exclude the diagnosis or minimize the severity of the metabolic disturbance.
Common pitfall: Urine ketones may rise or remain positive while DKA improves; interpreting that isolated change as treatment failure ignores conversion between different circulating ketone bodies.
Hyperglycaemic Crises in Adults with Diabetes: A Consensus Report
42.How does hypokalemia change the initial DKA treatment sequence?
DKA causes substantial total-body potassium depletion even when the initial serum value is normal or elevated. Insulin shifts potassium into cells and can make an already low concentration dangerously lower. The 2024 consensus recommends beginning potassium replacement and delaying insulin when potassium is below 3.5 mmol/L, until it rises above 3.5 mmol/L. Fluid treatment and close monitoring continue. This sequence prevents life-threatening arrhythmia and muscle weakness while preparing to treat the underlying insulin deficiency safely.
Apply it
An adult with DKA has potassium of 3.1 mmol/L. Begin appropriate fluids and potassium replacement with monitoring, and defer insulin until potassium exceeds 3.5 mmol/L rather than starting the usual insulin infusion immediately.
Common pitfall: Severe hyperglycemia does not justify ignoring low potassium. Insulin can worsen the immediate electrical danger before it corrects the metabolic disorder that prompted treatment.
Hyperglycaemic Crises in Adults with Diabetes: A Consensus Report
43.Which pregnancy and postpartum symptoms suggest serious pre-eclampsia?
Pre-eclampsia usually develops after 20 weeks and can first become apparent after birth. Severe persistent headache, visual disturbance, severe pain below the ribs, hypertension, and feeling markedly unwell require immediate assessment for multisystem disease. Proteinuria is common but organ involvement can occur without it. Delivery and previously normal prenatal blood pressures do not exclude postpartum presentation. Assess maternal symptoms, blood pressure, and organ function while considering other urgent causes.
Apply it
Five days after delivery, a patient with no antenatal hypertension develops severe headache and blurred vision. Check blood pressure and arrange urgent obstetric evaluation rather than attributing the symptoms to normal recovery.
Common pitfall: Neither a negative urine-protein result nor an uncomplicated pregnancy is sufficient reassurance when new warning symptoms are present.
44.What is magnesium sulfate's role in pre-eclampsia and eclampsia?
Magnesium sulfate is used to reduce the risk of eclamptic seizures in severe pre-eclampsia and to treat eclampsia when seizures have occurred. Its role is distinct from medications used to control severe hypertension. A patient may need both seizure-directed treatment and blood-pressure treatment, alongside specialist obstetric care. Recognizing these separate objectives prevents a common management error: assuming that lowering blood pressure alone supplies the anticonvulsant protection needed in a high-risk obstetric presentation.
Apply it
A patient admitted with severe pre-eclampsia receives medication for marked hypertension. Recognize that magnesium sulfate may also be required for seizure prevention; the antihypertensive does not perform the same therapeutic task.
Common pitfall: Do not describe magnesium sulfate as the primary blood-pressure drug. Seizure prevention and treatment of hypertension are related but separate components of managing severe pre-eclampsia.
45.How should acute heart-failure congestion be distinguished from stable chronic symptoms?
New dyspnea at rest, orthopnea, hypoxemia, or worsening edema in a patient with heart failure warrants assessment of congestion and perfusion. Significant fluid overload in hospitalized heart failure should be treated promptly with intravenous loop diuretics, with monitoring of urine output, renal function, and electrolytes. Evaluate precipitating factors such as ischemia, arrhythmia, infection, or medication problems. Hypotension with impaired perfusion raises concern for shock and requires emergency escalation rather than routine outpatient dose adjustment.
Apply it
A patient with HFrEF develops resting breathlessness, hypoxemia, crackles, and marked edema. Arrange emergency assessment and monitored treatment of decompensated heart failure rather than merely renewing the usual oral regimen.
Common pitfall: A diuretic treats congestion but does not replace foundational outcome therapy. Conversely, chronic medication optimization alone does not address acute respiratory or circulatory compromise.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
46.Which back-pain findings raise concern for cauda equina syndrome?
Cauda equina syndrome results from compression of the lower spinal nerve roots and can impair bladder, bowel, sexual, sensory, and motor function. New urinary retention, saddle sensory loss, or weakness involving multiple roots are important warning findings. Overflow leakage may occur from a distended bladder, so apparent incontinence does not rule out retention. The combination of back or leg pain with new sphincter or perineal symptoms requires immediate assessment rather than routine management of uncomplicated sciatica.
Apply it
A patient with worsening back pain reports loss of the usual urge to urinate and numbness when wiping. Treat these as possible sacral nerve-root dysfunction and arrange immediate evaluation for cauda equina compression.
Common pitfall: Urinary leakage can reflect an overfilled retained bladder. Do not interpret leakage as evidence that bladder emptying is intact or that compression is unlikely.
47.How should suspected cauda equina compression be investigated and treated?
Suspected cauda equina syndrome requires urgent MRI and specialist assessment. MRI defines the nerve roots and compressing soft-tissue lesion; plain radiographs cannot adequately answer this question. If local MRI is unavailable, arrange urgent transfer or coordinated alternative evaluation. Confirmed compression with neurologic dysfunction usually requires urgent or emergency decompression to preserve function. Analgesia can improve pain without relieving compression, so symptomatic relief does not remove the surgical urgency.
Apply it
A clinic patient has bilateral leg symptoms, new retention, and saddle numbness. Arrange immediate transfer for MRI and surgical assessment rather than ordering outpatient radiographs or waiting for a conservative-care trial.
Common pitfall: A normal radiograph or improved pain score does not exclude persistent compression or protect bladder, bowel, and motor function.
48.Which early-pregnancy symptoms require immediate evaluation for internal bleeding?
Ectopic pregnancy can cause unilateral lower abdominal pain, abnormal bleeding, shoulder-tip pain, faintness, or collapse. Shoulder-tip pain may reflect irritation from intra-abdominal blood. In a patient with unresolved pregnancy location, new severe pain or circulatory symptoms require emergency evaluation rather than waiting for scheduled hormone testing. Earlier stability or a previous nondiagnostic scan does not establish continued safety. Assess airway, breathing, circulation, and hemodynamic status while arranging urgent obstetric or surgical care.
Apply it
A patient awaiting repeat testing for pregnancy of unknown location develops increasing abdominal pain and shoulder-tip pain. Arrange immediate emergency assessment rather than waiting for the next hormone measurement.
Common pitfall: Hormone trends do not override clinical deterioration. Absence of a previously visualized ectopic pregnancy does not exclude rupture.
Preventive Care15%
49.When does USPSTF recommend colorectal cancer screening?
The 2021 USPSTF recommendation supports colorectal cancer screening for average-risk, asymptomatic adults aged 45–75 years. For ages 76–85, decisions are selective and consider overall health, prior screening, and preferences. Symptoms or a high-risk condition require a different evaluation pathway rather than mechanical application of routine screening ages. The age framework identifies a preventive population; it does not imply that a symptomatic younger patient should wait for screening eligibility before diagnostic investigation.
Apply it
An asymptomatic 46-year-old with average risk has never been screened. Offer a recommended screening strategy now rather than waiting until age 50, while confirming that the history does not require a different risk-based approach.
Common pitfall: Do not use screening age thresholds to defer evaluation of rectal bleeding or other concerning symptoms; preventive screening and diagnostic investigation answer different clinical questions.
50.How should colorectal screening test and interval be matched?
USPSTF recognizes several effective colorectal screening strategies with different intervals and practical requirements. Examples include annual FIT, stool DNA-FIT every one to three years, CT colonography every five years, and screening colonoscopy every ten years. Choosing a strategy requires discussing preparation, location, sedation, frequency, and the follow-up needed after an abnormal result. The interval belongs to the selected test and clinical context; it should not be transferred to another test simply because both screen for the same cancer.
Apply it
A patient prefers home stool testing and can reliably repeat it. Discuss annual FIT and the need for colonoscopy if positive, rather than offering FIT while incorrectly applying the ten-year interval associated with screening colonoscopy.
Common pitfall: A less invasive test does not eliminate repeated testing or follow-up obligations. Effectiveness depends on completing the chosen strategy at its recommended interval over time.
51.What should follow a positive stool-based colorectal screening test?
A positive stool-based screening result requires colonoscopy to complete evaluation and achieve the benefit of the screening strategy. Repeating the stool test cannot determine the source of the original abnormality or reliably exclude an important lesion. The clinical task changes from periodic screening to diagnostic follow-up. Before selecting a stool-based strategy, patients should understand this possible next step and practical arrangements should support completion rather than treating test ordering as the endpoint of prevention.
Apply it
An asymptomatic patient has a positive FIT and asks to repeat it because the result might be a false alarm. Arrange colonoscopy and explain why a later negative stool test would not resolve the original abnormality.
Common pitfall: False-positive results are possible, but repeating a screening test is not a valid substitute for the diagnostic examination required after a positive stool result.
52.How are USPSTF lung screening eligibility, exposure, and stopping rules applied?
The 2021 USPSTF framework recommends annual low-dose CT at ages 50–80 with at least 20 pack-years and current smoking or cessation within 15 years. Pack-years equal packs per day multiplied by years, adding periods when intensity changes: one pack daily for 12 years plus half a pack for 20 years equals 22 pack-years. Stop after 15 smoke-free years or when health substantially limits life expectancy or ability or willingness to undergo curative lung surgery. Discuss benefits, harms, and smoking cessation.
Apply it
An asymptomatic 61-year-old smoked half a pack daily for 40 years and quit eight years ago. The 20 pack-years and cessation history support annual low-dose CT if treatment remains feasible and desired.
Common pitfall: Chest radiography is not an equivalent screening test. Symptoms such as hemoptysis require diagnostic evaluation, and continued cancer risk alone does not justify screening when curative treatment is not feasible.
53.When should standardized developmental and autism screening occur?
AAP recommendations summarized by CDC call for standardized developmental screening at least at 9, 18, and 30 months and autism-specific screening at 18 and 24 months. Developmental surveillance continues during well-child care, and concerns warrant additional screening at any age. Complete missed scheduled screening at the next visit. A positive screen identifies a need for evaluation rather than establishing a diagnosis. See [CDC developmental monitoring and screening](https://www.cdc.gov/act-early/about/developmental-monitoring-and-screening.html).
Apply it
At an 18-month well-child visit, complete both general developmental and autism-specific screening, even when caregivers have not volunteered concerns.
Common pitfall: Autism screening does not replace assessment of language, motor, cognitive, and other developmental domains. Informal observation alone does not fulfill standardized screening.
54.How should a previous vaccine reaction influence the next vaccination decision?
Clarify the reaction's timing, manifestations, severity, and suspected component. A severe allergic reaction to a prior vaccine dose is generally a contraindication to another dose of that vaccine pending appropriate evaluation. Local soreness alone does not establish anaphylaxis. When the reaction suggests immediate allergy, specialist assessment can help determine the responsible component and whether future vaccination is possible. Every vaccination setting should have a plan and supplies for immediate recognition and treatment of anaphylaxis.
Apply it
A patient reports 'vaccine allergy.' Distinguish isolated arm soreness from a rapid episode of wheezing and hypotension before deciding whether routine vaccination or further allergy evaluation is appropriate.
Common pitfall: Do not turn every adverse event into a permanent allergy label, or give a repeat dose routinely after a credible severe allergic reaction without evaluation.
55.Which older women should receive osteoporosis screening?
The January 2025 USPSTF recommendation supports osteoporosis screening in women aged 65 years or older using DXA bone mineral density, with or without fracture-risk assessment. The recommendation concerns people without known osteoporosis or prior fragility fractures and does not replace evaluation of secondary causes. Screening identifies otherwise unrecognized skeletal risk before a fracture occurs. A woman need not report bone pain to qualify because osteoporosis can remain clinically silent until a fracture reveals the loss of bone strength.
Apply it
A 67-year-old woman has no known osteoporosis, fragility fracture, or secondary cause and feels well. Offer DXA screening rather than requiring pain, height loss, or another symptom before considering preventive assessment of skeletal health.
Common pitfall: Absence of symptoms does not establish low fracture risk. Conversely, a prior fragility fracture moves the patient beyond a simple routine screening question toward clinical evaluation.
56.How should younger postmenopausal women be selected for DXA?
For postmenopausal women younger than 65, USPSTF recommends a two-step approach. First identify risk factors such as low body weight, parental hip fracture, smoking, or excess alcohol use. Then use a clinical risk-assessment tool to determine whether risk is increased enough to warrant screening. This avoids both universal testing based only on menopause and dismissal based only on age. USPSTF does not define a single FRAX screening threshold, so treatment thresholds should not be misrepresented as screening rules.
Apply it
A 58-year-old postmenopausal woman has low body weight and a parent who sustained a hip fracture. Perform a structured risk assessment and use the result to decide on DXA rather than automatically waiting until 65.
Common pitfall: A fracture-treatment threshold is not automatically a screening threshold. Identify the purpose of the risk calculation before using a numerical cutoff to make a decision.
57.What does the USPSTF evidence statement for osteoporosis screening in men mean?
USPSTF concludes that evidence is insufficient to determine the balance of benefits and harms of routine osteoporosis screening in men. An insufficient-evidence statement is not a recommendation that screening is harmful or that skeletal disease should be ignored. Clinical evaluation remains appropriate when a man has a fragility fracture, suspected secondary osteoporosis, or other specific concerns. The distinction is between uncertainty about population screening outcomes and the separate obligation to assess an individual patient's clinical problem.
Apply it
A man asks whether USPSTF recommends routine osteoporosis screening for all men his age. Explain the insufficient-evidence statement, then assess his personal history rather than treating the statement as a prohibition on evaluating fracture risk.
Common pitfall: Insufficient evidence does not mean evidence of no benefit. It also does not justify ignoring a fragility fracture or a suspected secondary cause of bone loss.
Foundations of Care5%
58.How do absolute and relative risk reductions differ?
Absolute risk reduction subtracts the treated event risk from the comparator event risk. Relative risk reduction divides that absolute difference by the comparator risk. The same relative effect can produce very different absolute benefits when baseline risk differs. For clinical communication, show both groups' risks over the same time horizon, preferably using consistent denominators. This makes the size of benefit interpretable and prevents an impressive relative percentage from concealing a small change in the outcome a patient actually values.
Apply it
In a hypothetical five-year trial, an event occurs in 10% of controls and 8% of treated participants. Explain a two-percentage-point absolute reduction and a 20% relative reduction, keeping the outcome and follow-up period explicit.
Common pitfall: A 20% relative reduction does not mean 20 fewer events per 100 patients. Always recover the comparator risk before translating a relative effect into benefit.
Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions
59.How is number needed to treat calculated and interpreted?
Number needed to treat for one additional beneficial outcome is the reciprocal of absolute risk reduction expressed as a proportion. Round upward to a whole person when necessary. NNT must specify the comparator, outcome, and follow-up period because it is not a permanent property of a drug. It is an expected average, not a promise that precisely one person in each group of that size benefits. Different baseline risks can change NNT even when the relative treatment effect is similar.
Apply it
A hypothetical intervention reduces three-year hospitalization risk from 12% to 9%. The absolute reduction is 0.03, so NNT is 1/0.03, rounded up to 34 people treated for three years for one additional hospitalization avoided.
Common pitfall: Using the relative risk reduction in the reciprocal produces the wrong NNT. Omitting the follow-up period also makes otherwise correct arithmetic clinically incomplete and potentially misleading.
Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions
60.How should evidence support an informed and equitable care decision?
Evidence-based decisions combine expected benefits and harms with uncertainty, patient preferences, and practical access. Use understandable absolute risks and check comprehension instead of assuming that a recommendation guarantees informed agreement. Language, cost, and follow-up barriers can alter whether a plan is achievable. For covered US vaccines, required vaccine information statements support communication; federal provision requirements do not themselves mandate a signed consent form, although local rules may add requirements. Document the discussion and the patient's informed choice.
Apply it
A patient hesitates about vaccination and has limited English proficiency. Provide understandable information and language support, explore the specific concern, check understanding, and document the decision rather than treating a signature as sufficient evidence of informed choice.
Common pitfall: Agreement without comprehension is not meaningful shared decision-making. Do not equate a federal information-statement requirement with a universal federal requirement for signed vaccine consent forms.
Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions · CDC — Preventing and Managing Adverse Reactions
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official outline for full coverage: these concepts sample important decisions but do not replace study across adult, pediatric, maternity, gynecologic, mental-health, surgical, community, and older-patient care.
- Allocate review approximately 35% to acute diagnosis, 25% to chronic management, 20% to urgent care, 15% to prevention, and 5% to foundations, adjusting additional time toward demonstrated weaknesses.
- Practise discriminating cues: illness trajectory versus secretion color, childhood versus adult strep follow-up, otitis observation eligibility, canal-specific positional nystagmus, and clinical deterioration during unresolved pregnancy location.
- Link chronic prescriptions to individualized goals, exact drug selection, baseline safety checks, monitoring, and response criteria. Include routine diabetes and primary hypertension decisions alongside CKD, heart failure, and respiratory disease.
- Distinguish developmental surveillance, standardized screening, and diagnostic evaluation. Evaluate gynecologic symptoms using findings that distinguish vaginitis, cervicitis, PID, and pregnancy-related conditions.
- Rehearse emergencies as action sequences: recognize the threat, begin effective initial treatment, avoid harmful sequencing, and arrange definitive care.
- State the guideline framework when answering preventive questions, then check eligibility, interval, abnormal-result follow-up, contraindications, and stopping criteria.
- Treat the 20 questions and 20 cards as learning tools; use explanations and repeated reasoning rather than a small-sample score as evidence of readiness.
A practical preparation plan
1. Map the full examination scope
Read the current ABFM clinical-activity outline and place your existing review resources under all five domains. Identify disciplines absent from this selective guide so that familiar examples do not crowd out the examination's broader family-medicine scope.
2. Build comparison pairs
For acute topics, identify the finding that changes the decision: bacterial illness trajectory, age-specific strep follow-up, effusion and otitis severity, canal-specific nystagmus, vaginitis microscopy, or pelvic tenderness supporting presumptive PID treatment.
3. Create treatment-and-monitoring chains
For diabetes, hypertension, CKD, HFrEF, asthma, and mood disorders, connect treatment indications to individualized goals, exact drug selection, safety boundaries, monitoring, and reassessment. Include ACE inhibitor–ARNI washout and the combined maintenance-plus-reliever SMART ceiling.
4. Rehearse urgent sequences aloud
Explain first actions for anaphylaxis, hypoglycemia, DKA with low potassium, possible postpartum pre-eclampsia, acute heart-failure deterioration, ectopic warning symptoms, and cauda equina compression. State the finding that requires emergency escalation.
5. Complete and analyze the drills
Answer the questions before reading explanations. Record whether each error arose from missing a cue, using the wrong population, choosing the wrong sequence, or confusing screening with diagnosis. Revisit the related source and concept, then explain the corrected decision without looking.
6. Practise mixed clinical reasoning
Combine topics from different disciplines within each clinical-activity domain. Use recall cards for brief daily review and longer vignette sets for sustained concentration, expanding study beyond these examples as directed by the official outline.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABFM — One-Day Exam: Become Certified
- ABFM — One-Day Exam: Continue Certification
- 2026 Family Medicine Certification Examination Information Booklet
- ABFM — Family Medicine Exam Blueprint
- ABFM — New in 2025: Redesigned Family Medicine Exam Blueprint
- CDC — Outpatient Clinical Care for Adults
- CDC — Outpatient Clinical Care for Pediatric Populations
- CDC — Clinical Guidance for Group A Streptococcal Pharyngitis
- AAO-HNS — BPPV: Dix-Hallpike and Canalith Repositioning
- RCOG — Ectopic Pregnancy
- CDC — Clinical Features of Shingles
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Guideline Slide Set
- NHLBI — 2020 Focused Updates to the Asthma Management Guidelines
- NHLBI — COPD: Diagnosis
- NIMH — Mental Health Medications
- NIMH — Bipolar Disorder
- CDC — Preventing and Managing Adverse Reactions
- Hyperglycaemic Crises in Adults with Diabetes: A Consensus Report
- RCOG — Pre-eclampsia
- AANS — Cauda Equina Syndrome
- USPSTF — Colorectal Cancer: Screening
- USPSTF — Lung Cancer: Screening
- USPSTF — Osteoporosis to Prevent Fractures: Screening
- Cochrane Handbook — Chapter 15: Interpreting Results and Drawing Conclusions
- AOM Symptom Severity and Treatment Options | eqipp.aap.org
- CPG-BPPV08-05-2017.pdf
- Spirometry Quick Guide - Global Initiative for Chronic Obstructive Lung Disease - GOLD
- The A1C Test & Diabetes - NIDDK
- Managing Diabetes - NIDDK
- Low Blood Glucose (Hypoglycemia) - NIDDK
- Combination pills for high blood pressure may simplify treatment, improve long-term health | American Heart Association
- KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf
- 204629s063lbl.pdf
- 209803s008lbledt.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.